Skip to main content

Table 3 Relationship between the p73 (rs6695978 G > A) polymorphism and known clinicopathological variables of ovarian cancer

From: Polymorphisms in the p63 and p73 genes are associated with ovarian cancer risk and clinicopathological variables

Clinicopathological Variables

All

Genotype(%)

A allele frequency

Adjusteda

GG

GA+AA

P

OR (95 % CI)

Age

308

 

0.948

 

< 52

118

88 (74.6)

30 (25.4)

0.136

1.00 (ref)

≥52

190

146 (76.8)

44 (23.2)

0.137

2.87 (0.93-5.84)

Clinical stage

300

   

0.474

 

I-II

92

69 (75.0)

23 (25.0)

0.131

1.00 (ref)

III-IV

208

158 (76.0)

50 (24.0)

0.142

1.30 (0.89-1.93)

Tumor histology

308

 

0.003

 

Serous

196

150 (76.5)

46 (23.5)

0.128

 

1.00 (ref)

Mucinous

24

15 (62.5)

9 (37.5)

0.250

0.001

3.48 (1.15-6.83)

Endometrioid

22

17 (77.3)

5 (22.7)

0.114

0.337

2.25 (0.96-4.44)

Mixed/other

66

52 (78.8)

14 (21.2)

0.136

0.597

0.93 (0.76-1.19)

Degree of differentiation

246

 

0.005

 

High

28

22 (78.6)

6 (21.4)

0.107

 

1.00 (ref)

Medium

82

65 (79.3)

17 (20.7)

0.104

0.827

1.15 (0.86-1.69)

Low

136

98 (72.1)

38 (27.9)

0.162

0.003

1.87 (1.03-3.47)

Tumor behavior

294

 

0.838

 

Borderline

48

37 (77.1)

11 (22.9)

0.125

1.00 (ref)

Invasive

246

191 (77.6)

55 (22.4)

0.122

0.91 (0.79-1.03)

Lymph node statusb

176

 

0.010

 

Negative

62

50 (80.6)

12 (19.4)

0.105

1.00 (ref)

Positive

114

83 (72.8)

31 (27.2)

0.154

1.69 (1.14-2.75)

ERc

183

 

0.002

 

Negative

42

36 (85.7)

6 (14.3)

0.095

1.00 (ref)

Positive

141

100 (70.9)

41 (29.1)

0.163

2.72 (1.38-4.81)

PRc

171

 

0.329

 

Negative

66

49 (74.2)

17 (25.8)

0.144

 

1.00 (ref)

Positive

105

81 (77.1)

24 (22.9)

0.129

 

1.43 (0.76-2.32)

  1. a Logistic regression model adjusted for age, BMI, number liveborn, oral contraceptive use, cigarette smoking, ovarian cancer family history.
  2. b For advanced ovarian cancer patients, in terms of primary cytoreductive surgery, whether to simultaneously apply pelvic and para-aortic lymph node dissection is controversial. The general consensus that pelvic and para-aortic lymph node dissection does not increase the 5-year survival rate and improve prognosis has been widely accepted. Thus, some patients involved in our study only underwent primary cytoreductive surgery without pelvic and para-aortic lymph node dissection. The data regarding lymph node status in patients were partially missing.
  3. c Unlike breast cancer and endometrial cancer, the significance of ER and PR in the clinical treatment and prognosis of ovarian cancer is also valuable and disputed. Meanwhile, combined with the economic condition of the patients, some cases did not undergo ER and PR immunohistochemical analyses.
  4. All statistical tests were two-sided with a significance level of P ≤ 0.05.